This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Colorectal cancer; colitis	c-Src tyrosine kinase (CSK)	<p>Mouse studies suggest activating CSK could help treat colitis and colon cancer. In a mouse model for chemical-induced colitis and colon cancer, a diet including the plant flavonoid isorhamnetin resolved colitis and decreased tumor burden and increased survival compared with a control diet. In colorectal cancer cells, isorhamnetin activity was dependent on increased CSK expression and signaling. Next steps could include identifying the molecular target of isorhamnetin and testing the compound in additional colon cancer models.</p> <p>SciBX 6(30); doi:10.1038/scibx.2013.802 Published online Aug. 8, 2013</p>	Patent and licensing status unavailable	<p>Saud, S.M. <i>et al. Cancer Res.</i>; published online July 1, 2013; doi:10.1158/0008-5472.CAN-13-0525 Contact: Matthew R. Young, National Cancer Institute, Frederick, Md. e-mail: youngma@mail.nih.gov</p>